RankingsPricing
  1. US-listed companies
  2. Zivo Bioscience, Inc.

Zivo Bioscience, Inc.ZIVO

Market cap
$25.47M
P/E ratio
Back to summarized table
Income statementBalance sheetCash flow
Dec 31,
2011		Dec 31,
2012		Dec 31,
2013		Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022
NET LOSS-2,731,610-3,248,405-10,095,878680,811-5,789,131-6,059,627-10,038,374-14,635,367-11,510,166-9,105,729-9,163,366-8,745,293
Stock issued for services rendered------1,217,369822,001759,3782,302,04432,775-
Gain of forgiveness of debt and accrued interest-------406,482---122,520-
Employee and director equity-based compensation expense----------33
Non-cash lease expense----------22,13879,637
Amortization of deferred R&D obligations - participation agreements-----------555,745774,025
Prepaid expenses443--63,42140,39819,383-1,0961,7057,4736666,672-28,12544,338
Security deposits1,565-122,917845--------29,058
Accounts payable-------124,656-119,285950,002187,199-905,295-163,663
Lease liabilities------------51,695
Accrued liabilities13,176-----5,6301,312,1882,098,4191,520,441654,460483,160-66,639
Net cash (used) in operating activities-1,294,128--2,986,214-2,736,046-2,296,887-2,543,473-4,242,891-5,006,586-3,707,297-2,588,415-6,803,333-7,102,612
Net cash (used) in investing activities-4,720--331,377---------
Proceeds of loans payable, other24,306---2,067,500-148,040-217,614--190,500628,600
Payment of loans payable, other----------190,500628,600
Proceeds from sale of common stock warrants - participation agreements----------55,697-
Expenses related to public offering----------2-
Proceeds from sales of common stock617,500------3,433,8132,650,000400,8662-
Net cash provided by financing activities1,508,938-3,763,5472,244,3252,312,0933,033,8704,053,0405,078,3423,664,5172,380,16616-
Increase (decrease) in cash----------9-7,102,612
Interest----------3,08410,920
Income taxes------------